Program
icotrokinra
Also written as “JNJ-77242113”, “Icotrokinra” and “PN-235”.
Its studies are mostly in Psoriasis · Arthritis, Psoriatic · Colitis, Ulcerative · Crohn Disease, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Johnson & Johnson | 137 open or running | phase 3since Oct 18, 2023 | Sep 21, 2021 | Feb 10, 2027phase 3 · NCT06807424 |
| Protagonist Therapeutics | 10 open or running | phase 1since Oct 29, 2020 | Oct 29, 2020 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 29, 2020First study: phase 1 study in Healthy VolunteersNew to Protagonist TherapeuticsProtagonist Therapeutics · NCT04621630 · 107 enrolled · Australia
- Sep 21, 2021Johnson & Johnson's first study: phase 1 study in HealthyNew to Johnson & JohnsonJohnson & Johnson · NCT05062200 · 36 enrolled · Japan
- Jan 24, 2022Phase 2 study in Plaque PsoriasisJohnson & Johnson · NCT05223868 · 255 enrolled · United States, Canada, France and more
- Apr 27, 2022Phase 2 study in Plaque PsoriasisJohnson & Johnson · NCT05357755 · 90 enrolled · United States, Canada, France and more
- May 3, 2022Phase 2 study in Plaque PsoriasisJohnson & Johnson · NCT05364554 · 227 enrolled · United States, Canada, France and more
- Jan 20, 2023Phase 1 study in HealthyJohnson & Johnson · NCT05703841 · 30 enrolled · China
- Sep 15, 2023Phase 2 study in Colitis, UlcerativeJohnson & Johnson · NCT06049017 · 252 enrolled · United States, Argentina, Australia and more
- Oct 18, 20232 phase 3 studies in Plaque PsoriasisJohnson & Johnson · NCT06095115, NCT06095102
- Feb 29, 2024Phase 3 study in PsoriasisJohnson & Johnson · NCT06295692 · 19 enrolled · Japan
- Jan 29, 2025Phase 3 study in Arthritis, PsoriaticJohnson & Johnson · NCT06807424 · 813 enrolled · United States, Argentina, Australia and more
- Mar 13, 2025Phase 3 study in Arthritis, PsoriaticJohnson & Johnson · NCT06878404 · 552 enrolled · United States, Argentina, Australia and more
- Sep 22, 20252 phase 3 studiesJohnson & Johnson · NCT07196748, NCT07196722
Ahead
- Feb 10, 2027Primary completion: phase 3 study in Arthritis, PsoriaticJohnson & Johnson · NCT06807424
- Jan 14, 2028Primary completion: phase 3 study in Colitis, UlcerativeJohnson & Johnson · NCT07196748
- Sep 19, 2028Primary completion: phase 3 study in Crohn DiseaseJohnson & Johnson · NCT07196722
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 14 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07196748Colitis, Ulcerative · United States, Argentina, Australia and more | 3 | Active, not recruiting | Johnson & Johnson | Jan 14, 2028 | 896 |
| NCT07196722Crohn Disease · United States, Argentina, Australia and more | 3 | Recruiting | Johnson & Johnson | Sep 19, 2028 | 1,092 |
| NCT06878404Arthritis, Psoriatic · United States, Argentina, Australia and more | 3 | Active, not recruiting | Johnson & Johnson | May 25, 2026 | 552 |
| NCT06807424Arthritis, Psoriatic · United States, Argentina, Australia and more | 3 | Active, not recruiting | Johnson & Johnson | Feb 10, 2027 | 813 |
| NCT06295692Psoriasis · Japan | 3 | Active, not recruiting | Johnson & Johnson | Jan 14, 2025 | 19 |
| NCT06095115Plaque Psoriasis · United States, Argentina, Australia and more | 3 | Active, not recruiting | Johnson & Johnson | Jul 29, 2024 | 684 |
| NCT06095102Plaque Psoriasis · United States, Argentina, Canada and more | 3 | Active, not recruiting | Johnson & Johnson | Jun 19, 2024 | 311 |
| NCT06049017Colitis, Ulcerative · United States, Argentina, Australia and more | 2 | Completed | Johnson & Johnson | Sep 26, 2024 | 252 |
| NCT05703841Healthy · China | 1 | Completed | Johnson & Johnson | Apr 7, 2023 | 30 |
| NCT05364554Plaque Psoriasis · United States, Canada, France and more | 2 | Completed | Johnson & Johnson | Sep 29, 2023 | 227 |
| NCT05357755Plaque Psoriasis · United States, Canada, France and more | 2 | Completed | Johnson & Johnson | Mar 23, 2023 | 90 |
| NCT05223868Plaque Psoriasis · United States, Canada, France and more | 2 | Completed | Johnson & Johnson | Dec 15, 2022 | 255 |
| NCT05062200Healthy · Japan | 1 | Completed | Johnson & Johnson | Sep 28, 2022 | 36 |
| NCT04621630Healthy Volunteers · Australia | 1 | Completed | Protagonist Therapeutics | Sep 19, 2021 | 107 |
How it is read
Names in the registry
- “JNJ-77242113”, 9 entries
- “Icotrokinra”, 4 entries
- “PN-235”, 1 entry
Codes read as this program: PN235.
Conditions, from the studies’ own filings
- Psoriasis, 6 studies
- Arthritis, Psoriatic, 2 studies
- Colitis, Ulcerative, 2 studies
- Crohn Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.